Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide drugs in Denmark. Its principal product is Lixisenatide, a novel once-daily glucagon-like peptide (GLP)-1 agonist for the treatment of type 2 diabetes; The company’s product pipeline also comprise Lixisenatide/Lantus, a GLP-1 basal insulin combination product for the treatment of patients with type 2 diabetes; and ZP2929, a once-daily dual acting glucagon/GLP-1 peptide agonist for the treatment of diabetes and/or obesity. In addition, it is developing Elsiglutide, a GLP-2 peptide agonist for the prevention of chemotherapy induced diarrhea; ZP1480, an MSH melanocortin peptide agonist for the prevention of acute kidney injury following surgery; danegaptide, a dipeptide gap junction modifier with cardioprotective properties; and ZP1848, a GLP-2 peptide agonist for the treatment of Inflammatory Bowel Disease. Further, the company has peptide drug programs in various stages of research and pre-clinical development, primarily in the field of diabetes/metabolic diseases. Zealand Pharma A/S has collaboration agreements with Sanofi S.A.; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; and AbbVie. The company was incorporated in 1997 and is based in Copenhagen, Denmark.
zealand pharma a/s (ZEAL:Copenhagen)
Phone: 45 88 77 36 00
Fax: 45 88 77 38 98zealandpharma.com
|No competitor information is available for ZEAL.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA |Posted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
- New York, NY | AGORAPosted: Nov 25
Sponsored Financial Commentaries
To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.